Paper Details

  1. Home
  2. Paper Details

Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.

Author: ChuangHui-Yen, HwangJeng-Jong, LeeYen-Po, TyanYeu-Sheng, WangWei-Hsun

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Orlistat, an FASN inhibitor, enhanced the cytotoxic effects of enzalutamide and inhibited tumor growth in a PC3 prostate cancer cell line and tumor-bearing mouse model. The combination treatment reduced both FASN and NF-κB activities and their downstream effector proteins, suggesting a synergistic effect.
Paper Details　
Original Abstract of the Article :
Androgen deprivation therapy (ADT) is one of the typical treatments used for patients with prostate cancer (PCa). ADT, however, may fail when PCa develops castration-resistance. Fatty acid synthase (FASN), a critical enzyme involved in fatty acid synthesis, is found to be up-regulated in PCa. Since ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164108/

データ提供：米国国立医学図書館（NLM）

A Multi-Pronged Attack on Prostate Cancer

Prostate cancer, a common and often aggressive disease, poses a significant challenge to healthcare providers. This study investigates the potential of combining orlistat, an inhibitor of fatty acid synthase (FASN), with enzalutamide and castration in the treatment of prostate cancer. The researchers found that this combination therapy exhibits synergistic effects in both in vitro and in vivo models, effectively inhibiting tumor growth and reducing FASN activity.

A New Frontier in Prostate Cancer Therapy

The research highlights the potential of orlistat as a key player in prostate cancer therapy. By targeting FASN, a critical enzyme involved in tumor growth, orlistat could potentially enhance the efficacy of existing treatments and provide a more comprehensive approach to managing this disease.

A Promising Avenue for Future Research

This study, like a compass guiding researchers through the vast desert of prostate cancer research, points to a promising new avenue for therapeutic development. The synergistic effects of this combination therapy open up exciting possibilities for future research and clinical trials.

Dr. Camel's Conclusion

This research, like a well-placed oasis in the arid landscape of prostate cancer, offers a ray of hope for patients. The synergistic effects of this combination therapy suggest a more effective and comprehensive approach to managing this disease, paving the way for improved patient outcomes.

Date :
  1. Date Completed 2021-12-20
  2. Date Revised 2021-12-20
Further Info :

Pubmed ID

33974005

DOI: Digital Object Identifier

PMC8164108

Related Literature

Article Analysis
・Effects of enzalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.